181 related articles for article (PubMed ID: 11855885)
1. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
Taylor DD; Lyons KS; Gerçel-Taylor C
Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
[TBL] [Abstract][Full Text] [Related]
2. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors.
Taylor DD; Gerçel-Taylor C; Lyons KS; Stanson J; Whiteside TL
Clin Cancer Res; 2003 Nov; 9(14):5113-9. PubMed ID: 14613988
[TBL] [Abstract][Full Text] [Related]
3. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated serum globulin determined in patients with cervical, endometrial and ovarian cancer.
Altarac S
Acta Med Croatica; 1993; 47(1):19-22. PubMed ID: 7693081
[TBL] [Abstract][Full Text] [Related]
6. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
[TBL] [Abstract][Full Text] [Related]
7. Plasma calprotectin concentrations in women with endometrial carcinoma.
Ni Bhriain H; Trovik J; Wik E; Stefansson IM; Akslen LA; Salvesen HB; Staff AC
Gynecol Oncol; 2009 Sep; 114(3):491-5. PubMed ID: 19577278
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
9. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
[TBL] [Abstract][Full Text] [Related]
10. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
12. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
13. Plasma bikunin as a favorable prognostic factor in ovarian cancer.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
J Clin Oncol; 2005 Mar; 23(7):1463-72. PubMed ID: 15735122
[TBL] [Abstract][Full Text] [Related]
14. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
15. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Soini Y; Turpeenniemi-Hujanen T; Santala M
Gynecol Oncol; 2007 Jan; 104(1):217-21. PubMed ID: 16996112
[TBL] [Abstract][Full Text] [Related]
16. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage.
Aglund K; Rauvala M; Puistola U; Angström T; Turpeenniemi-Hujanen T; Zackrisson B; Stendahl U
Gynecol Oncol; 2004 Sep; 94(3):699-704. PubMed ID: 15350361
[TBL] [Abstract][Full Text] [Related]
17. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.
Sood AK; Fletcher MS; Coffin JE; Yang M; Seftor EA; Gruman LM; Gershenson DM; Hendrix MJ
Am J Obstet Gynecol; 2004 Apr; 190(4):899-909. PubMed ID: 15118611
[TBL] [Abstract][Full Text] [Related]
18. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
19. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
Arts HJ; de Jong S; Hollema H; Ten Hoor KA; de Vries EG; van der Zee AG
Int J Oncol; 2005 Feb; 26(2):379-84. PubMed ID: 15645122
[TBL] [Abstract][Full Text] [Related]
20. Serum evaluation of P53 protein in patients with gynaecological cancer.
Barbati A; Mariani L; Porpora MG; Anceschi M; Collini P; Lauro V; Cosmi EV
Anticancer Res; 2000; 20(2A):1033-5. PubMed ID: 10810393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
